Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge
- PMID: 23510034
- DOI: 10.3928/23258160-20130313-01
Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge
Abstract
This editorial describes the challenge of managing eyes that demonstrate signs of persistent exudation after anti-VEGF treatment and illuminates the significance of a new report of using high-dose ranibizumab in treating recalcitrant neovascular age-related macular degeneration.
Copyright 2013, SLACK Incorporated.
Comment on
-
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results.Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr;44(2):121-6. doi: 10.3928/23258160-20130313-04. Ophthalmic Surg Lasers Imaging Retina. 2013. PMID: 23510037 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
